CN107080751A - A kind of Western medicine compound for treating hypertrophic osteoarthropathy and its application - Google Patents
A kind of Western medicine compound for treating hypertrophic osteoarthropathy and its application Download PDFInfo
- Publication number
- CN107080751A CN107080751A CN201710289973.5A CN201710289973A CN107080751A CN 107080751 A CN107080751 A CN 107080751A CN 201710289973 A CN201710289973 A CN 201710289973A CN 107080751 A CN107080751 A CN 107080751A
- Authority
- CN
- China
- Prior art keywords
- western medicine
- parts
- medicine compound
- treatment
- hypertrophic osteoarthropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
Abstract
The invention discloses a kind of Western medicine compound for treating hypertrophic osteoarthropathy and its application, the Western medicine compound is according to mass fraction meter, and its active component is composed of the following components：24 28 parts of 9 13 parts of maytanprine, 30 42 parts of paracetamol and Ribavirin, adult's dosage of active component is 1.2 1.3mg/kg/ days.Western medicine compound of the present invention is using maytanprine, paracetamol and Ribavirin as raw material, with removing toxic substances except heat, dampness elimination analgesic effect, osteoproliferation can be released to nerve root compression, only quickly alleviating pain, fiber crops, the osteoproliferation neoplasm repaired neuratorphy, dissolve protrusion, problem is solved from source, verify that its cure rate to hypertrophic osteoarthropathy is 77.5 90.0% through clinical treatment, total effective rate is 100%, and safety is without obvious adverse reaction.
Description
Technical field
The present invention relates to technical field of western medicines, specifically a kind of Western medicine compound for treating hypertrophic osteoarthropathy and its should
With.
Background technology
Hypertrophic osteoarthropathy refers to due to degeneration of joint, so that chronic joint caused by articular cartilage is destroyed
Disease.Also known as degenerative arthritis, osteoarthritis and hypertrophiarthritis etc..This sick onset is slow, no constitutional symptom, mostly 50 years old
Person in middle and old age above.Often it is multi-joint morbidity, also has simple joint to send out patient.Affected joints can have continuation secret anguish, activity increase
Shi Jiachong, takes a turn for the better after rest.Pain is not often serious, and air pressure is aggravated when reducing, relevant with climate change.Sometimes there can be Acute Pain
Breaking-out, while there is joint stiff sense, can find intra-articular there is crunch once in a while.Sitting posterior joint is stiff to be aggravated, slightly good after activity
Turn, someone is referred to as " rest pain ".Later stage arthroncus, increase and limitation of movement, seldom complete tetanus normally behave as bone resistance
It is stagnant to levy.
Hypertrophic osteoarthropathy is apt to occur in the person in middle and old age of more than 40 years old and is engaged in load-bearing, long station, the staff of sitting, with
The larger joint of scope of activities, vertebra lesion it is common.The cause of disease of hypertrophic osteoarthropathy is unknown so far, belongs to senile more
The category of retrogression pathological changes, a lot of on its etiology and pathogenesis hypothesis, such as machinery is said, function is said, vascular disorder, metabolism barrier
Hinder, dysendocrinism etc..Basic understandings are on interior gene basis, to cause morbidity by the induction of external cause.Current doctor trained in Western medicine is using non-
Steroids antiinflammation pain-stopping pharmaceutical, physiotherapy and operative treatment, there is certain effect to relief of symptoms, but there is no special effective treatment so far
Method.
The content of the invention
There is removing toxic substances except the Hypertrophic Bones and joints for the treatment of of heat, dampness elimination analgesic effect it is an object of the invention to provide a kind of
The Western medicine compound of disease and its application.
To achieve the above object, the present invention provides following technical scheme：
A kind of Western medicine compound for treating hypertrophic osteoarthropathy, according to mass fraction meter, its active component is by following components group
Into：24-28 parts of 9-13 parts of maytanprine, 30-42 parts of paracetamol and Ribavirin.
It is used as further scheme of the invention：According to mass fraction meter, its active component is composed of the following components：Mei Dengpu
25-26 parts of 9-11 parts of woods, 36-39 parts of paracetamol and Ribavirin.
It is used as further scheme of the invention：According to mass fraction meter, its active component is composed of the following components：Mei Dengpu
26 parts of 10 parts of woods, 38 parts of paracetamol and Ribavirin.
It is used as further scheme of the invention：Adult's dosage of the active component of described Western medicine compound is 1.2-
1.3mg/kg/ day.
It is used as further scheme of the invention：Adult's dosage of the active component of described Western medicine compound is
1.23mg/kg/ day.
It is used as further scheme of the invention：Described Western medicine compound is peroral dosage form.
It is used as further scheme of the invention：Described peroral dosage form is tablet.
Application of the described Western medicine compound in terms for the treatment of hypertrophic osteoarthropathy medicine is prepared.
The drug effect of component used of the invention is as follows：
Maytanprine：It is naturally occurring in Celastraceae plant Maytenus hookeri (Maytersus hoakeri l.caes), the southern regions of the Yunnan Province
In the grade plants of Caulis Mayteni (M.uustruyu-naauneasis S. ,] .Pei et Y.H.Li 1.With antitumaous effect, for resisting
Tumour, effect is strong.Toxicity is low.
Paracetamol：Molecular formula C8H9NO2, usually white crystalline powder, there is antipyretic effect, for feeling
Emit fever, arthralgia, neuralgia, antimigraine, pain caused by cancer and postoperative analgesia etc..
Ribavirin：It is the antiviral drugs of broad spectrum high-effect, is now widely used for the preventing and treating of viral disease.Conventional agent
Type has injection, tablet, oral liquid, aerosol etc..
Compared with prior art, the beneficial effects of the invention are as follows：Western medicine compound of the present invention is with maytanprine, to acetyl ammonia
Base phenol and Ribavirin are raw material, with removing toxic substances except heat, dampness elimination analgesic effect, can release osteoproliferation to nerve root compression,
Quickly alleviating pain, only fiber crops, the osteoproliferation neoplasm repaired neuratorphy, dissolve protrusion, problem is solved from source, is controlled through clinic
It is 77.5-90.0% to treat checking its cure rate to hypertrophic osteoarthropathy, and total effective rate is 100%, and safety is without substantially bad anti-
Should.
Embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of Western medicine compound for treating hypertrophic osteoarthropathy, according to mass fraction meter, its activity into
Divide composed of the following components：28 parts of 9 parts of maytanprine, 30 parts of paracetamol and Ribavirin.
Embodiment 2
In the embodiment of the present invention, a kind of Western medicine compound for treating hypertrophic osteoarthropathy, according to mass fraction meter, its activity into
Divide composed of the following components：24 parts of 13 parts of maytanprine, 42 parts of paracetamol and Ribavirin.
Embodiment 3
In the embodiment of the present invention, a kind of Western medicine compound for treating hypertrophic osteoarthropathy, according to mass fraction meter, its activity into
Divide composed of the following components：26 parts of 9 parts of maytanprine, 36 parts of paracetamol and Ribavirin.
Embodiment 4
In the embodiment of the present invention, a kind of Western medicine compound for treating hypertrophic osteoarthropathy, according to mass fraction meter, its activity into
Divide composed of the following components：25 parts of 11 parts of maytanprine, 39 parts of paracetamol and Ribavirin.
Embodiment 5
In the embodiment of the present invention, a kind of Western medicine compound for treating hypertrophic osteoarthropathy, according to mass fraction meter, its activity into
Divide composed of the following components：26 parts of 10 parts of maytanprine, 38 parts of paracetamol and Ribavirin.
In above-described embodiment, the preparation process of the Western medicine compound of described treatment hypertrophic osteoarthropathy is：Stepped on U.S.A
Pu Lin, paracetamol and Ribavirin are active component, using acceptable technique and auxiliary material in pharmacy, are made oral
Tablet.
Drug toxicology is tested
1st, acute toxicity test
Using tablet made from the embodiment of the present invention 5 as experiment, using gastric infusion mode, successive administration 3 times in 24h, every time
4h is spaced, every time administration 41mg active components, accumulation medicine total amount reaches 123mg active components/kg, equivalent to people's quantity
100 times.After administration in 7d, mouse activity, feed, normal, the well-grown of excretion, hair color light, its average weight is with reality
Test the extension of time and increase.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain, thymus gland, stomach,
Intestines etc. do not find color and paramophia, fail to measure median lethal dose（LD50）.As a result show：Western medicine compound of the present invention
Without acute toxic reaction.
2nd, long term toxicity test
Using tablet made from the embodiment of the present invention 5 as experiment, using gastric infusion mode, Western medicine compound of the present invention is divided into low
Dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 15.375,30.75,61.5mg active components/kg/d,
Equivalent to clinical dosage 15,30,60 times.After gastric infusion 12 weeks, general status, blood of the Western medicine compound of the present invention to animal
Liquid index, blood parameters are without obvious influence, and Systematic anatomy, organ coefficient and histopathological examination are not also found
Abnormal pathologic changes.Drug withdrawal also has no obvious change in 2 weeks.As a result show：Western medicine compound of the present invention in long term toxicity test,
Overt toxicity reaction and delayed toxicity reaction are not found.It can be seen that, Western medicine compound non-toxic reaction of the present invention, long-term prescription safety
Reliably.
Clinical test
1st, basic document
The hypertrophic osteoarthropathy patient 280 made a definite diagnosis through outpatient service, wherein male 168, women 112 are chosen, the age is in 42-
Between 68 years old, average age is 54 years old, and 280 patients are randomly divided into treatment 1-5 groups, totally seven groups, every group 40 of control 1-2 groups
Gender, age and symptom no significant difference between example, each group, with comparativity.
Diagnostic criteria：Piece inspection, which is taken the photograph, through x-ray or CT lumbar vertebraes is diagnosed as lumbar vertebrae hyperosteogeny；All patients have chronic back pain
Medical history；Some patientss are with symptoms such as numbness of lower limbs or pain.
2nd, treatment method
Treat 1-5 groups：Take the worth tablets of embodiment 1-5 respectively, twice daily, a point early, evening takes, each taking equivalent to
0.615mg active components/kg dosage.1 month is a course for the treatment of, and the 3-5 course for the treatment of takes effect.
Compare 1 group：The tablet taken only contains two kinds of components of paracetamol and Ribavirin, remaining and embodiment 5
It is identical.Twice daily, early, evening is divided to take, each taking the dosage equivalent to 0.535mg active components/kg.It is within 1 month
One course for the treatment of, the 3-5 course for the treatment of takes effect.
Compare 2 groups：The tablet taken only contains a kind of component of maytanprine, and remaining is identical with embodiment 5.Daily two
Secondary, a point early, evening takes, each taking the dosage equivalent to 0.08mg active components/kg.It is within 1 month a course for the treatment of, 3-5 treatment
Cheng Jianxiao.
3rd, efficacy assessment standard
Cure：X-ray or CT check contrast spur disappear, can extensive recovery operation, more than 2 kilometers without pain diseases of energy activity or walking
Shape；
Take a turn for the better：Arthralgia mitigates, and movable function is obviously improved；
It is invalid：Symptom, sign are without improvement.
4th, therapeutic effect
The treatment comparitive study of each group of table 1
| Project | Case load | Cure number | Improvement number | Invalid number | Cure rate | Total effective rate |
| Treat 1 group | 40 | 31 | 9 | 0 | 77.5% | 100% |
| Treat 2 groups | 40 | 32 | 8 | 0 | 80.0% | 100% |
| Treat 3 groups | 40 | 34 | 6 | 0 | 85.0% | 100% |
| Treat 4 groups | 40 | 35 | 5 | 0 | 87.5% | 100% |
| Treat 5 groups | 40 | 36 | 4 | 0 | 90.0% | 100% |
| Compare 1 group | 40 | 4 | 19 | 17 | 10.0% | 57.5% |
| Compare 2 groups | 40 | 0 | 6 | 34 | 0.0% | 15.0% |
After treatment by 5 courses for the treatment of, the curative effect of each group is as shown in table 1：The cure rate for the treatment of group is 77.5-90.0%, total effective
Rate is 100%；Compared with control group, the cure rate and total effective rate for the treatment of group are far superior to control group, and difference has statistics meaning
Justice（P ＜ 0.05）；By 5 groups of comparison therapy and control 1-2 groups, it is found that maytanprine has not in Western medicine compound of the present invention
Alternatively, important effect, maytanprine has obvious synergistic function with remaining component in Western medicine compound of the present invention.
And in whole therapeutic process, obvious adverse reaction does not occur for each group.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Using specification as an entirety, the technical solutions in the various embodiments may also be suitably combined, forms those skilled in the art
It may be appreciated other embodiment.
Claims (8)
1. a kind of Western medicine compound for treating hypertrophic osteoarthropathy, it is characterised in that according to mass fraction meter, its active component
It is composed of the following components：24-28 parts of 9-13 parts of maytanprine, 30-42 parts of paracetamol and Ribavirin.
2. the Western medicine compound for the treatment of hypertrophic osteoarthropathy according to claim 1, it is characterised in that according to mass parts
Number meter, its active component is composed of the following components：9-11 parts of maytanprine, 36-39 parts of paracetamol and Ribavirin 25-
26 parts.
3. the Western medicine compound for the treatment of hypertrophic osteoarthropathy according to claim 2, it is characterised in that according to mass parts
Number meter, its active component is composed of the following components：26 parts of 10 parts of maytanprine, 38 parts of paracetamol and Ribavirin.
4. according to the Western medicine compound of any described treatment hypertrophic osteoarthropathies of claim 1-3, it is characterised in that described
Western medicine compound active component adult's dosage be 1.2-1.3mg/kg/ days.
5. the Western medicine compound for the treatment of hypertrophic osteoarthropathy according to claim 4, it is characterised in that described Western medicine
Adult's dosage of the active component of composition is 1.23mg/kg/ days.
6. the Western medicine compound for the treatment of hypertrophic osteoarthropathy according to claim 4, it is characterised in that described Western medicine
Composition is peroral dosage form.
7. the Western medicine compound for the treatment of hypertrophic osteoarthropathy according to claim 6, it is characterised in that described is oral
Formulation is tablet.
8. according to any described Western medicine compounds of claim 1-3 answering in terms for the treatment of hypertrophic osteoarthropathy medicine is prepared
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710289973.5A CN107080751A (en) | 2017-04-27 | 2017-04-27 | A kind of Western medicine compound for treating hypertrophic osteoarthropathy and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710289973.5A CN107080751A (en) | 2017-04-27 | 2017-04-27 | A kind of Western medicine compound for treating hypertrophic osteoarthropathy and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107080751A true CN107080751A (en) | 2017-08-22 |
Family
ID=59613082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710289973.5A Withdrawn CN107080751A (en) | 2017-04-27 | 2017-04-27 | A kind of Western medicine compound for treating hypertrophic osteoarthropathy and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107080751A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940700A (en) * | 2010-09-20 | 2011-01-12 | 桂兰仙 | Dai nationality medicine for treating rheumatism |
| CN105497098A (en) * | 2015-12-21 | 2016-04-20 | 江苏省中国科学院植物研究所 | Monimopetalum Chinese extract with anti-inflammatory activity, preparing method and application of extract |
| CN107406463A (en) * | 2014-12-04 | 2017-11-28 | 细胞基因公司 | biomolecule conjugate |
-
2017
- 2017-04-27 CN CN201710289973.5A patent/CN107080751A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940700A (en) * | 2010-09-20 | 2011-01-12 | 桂兰仙 | Dai nationality medicine for treating rheumatism |
| CN107406463A (en) * | 2014-12-04 | 2017-11-28 | 细胞基因公司 | biomolecule conjugate |
| CN105497098A (en) * | 2015-12-21 | 2016-04-20 | 江苏省中国科学院植物研究所 | Monimopetalum Chinese extract with anti-inflammatory activity, preparing method and application of extract |
Non-Patent Citations (1)
| Title |
|---|
| 唐辉等: "美登木属药用植物研究进展", 《湖北农业科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bone et al. | Ginger root—a new antiemetic The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery | |
| Hensley et al. | American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants | |
| AU2016201325B2 (en) | Methods Of Providing Weight Loss Therapy In Patients With Major Depression | |
| CN107530317A (en) | The combination of Cannabinoids and N acyl ethanol amines | |
| KR101900520B1 (en) | A combination composition | |
| Kesten et al. | Patient handling of a multidose dry powder inhalation device for albuterol | |
| EP2341900B1 (en) | A medicinal product and treatment | |
| PT2877192T (en) | Compositions for treatment of cancer-related fatigue | |
| CN107080751A (en) | A kind of Western medicine compound for treating hypertrophic osteoarthropathy and its application | |
| CN108992549A (en) | A kind of pharmaceutical composition and preparation method thereof, application | |
| Khan et al. | Prophylactic use of gabapentin to reduce postoperative nausea and vomiting in patients undergoing diagnostic gynecological laparoscopy | |
| CN106852932A (en) | A kind of medicine for treating cirrhotic ascites | |
| CN106389439A (en) | Chinese and western medicine composition for curing liver cirrhosis ascites, and preparation method and application thereof | |
| Meiser et al. | A Randomized Controlled Trial Comparing Inhaled Isoflurane Via the Anaesthetic Conserving Device (Sedaconda® ACD) with Propofol for Sedation of Invasively Ventilated ICU Patients | |
| Serrano et al. | Analgesic efficacy of associating a sciatic block to a femoral block in the posotperative period of total knee arthroplasty: 8AP4-9 | |
| Hawks et al. | Is bupropion an effective intervention for preventing seasonal affective disorder? | |
| Montazeri et al. | 3073 Quality of life in patients with gastric cancer: psychometric properties of the Iranian version of the EORTC QLQ-STO22 | |
| Hassan et al. | Comparative Study between Caudal Analgesia, Rectus Sheath Block and Local Wound Infiltration in Pediatric Undergoing Umbilical Hernia Repair | |
| Hussien et al. | Dexmedetomidine compared to ketofol for sedation in pediatric patients undergoing dental procedures: a double-blind, randomized clinical trial | |
| CN102648917A (en) | Application of vitamin D3 in preparing medicine for treating multiple myeloma | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN103315989B (en) | A kind of pharmaceutical composition | |
| CN105902538A (en) | Medicine composition for treating or preventing oral ulcer, preparation method and application thereof | |
| CN102716129B (en) | Application of ligustrazine to medicines for adjuvant therapy of rheumatoid diseases | |
| CN106619604A (en) | Medicine for treating or preventing dental ulcer, and application of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170822 |